{
    "id": 25283,
    "fullName": "ATF7IP - PDGFRB",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ATF7IP-PDGFRB results from the fusion of ATF7IP and PDGFRB, demonstrating constitutive kinase activity, activation of downstream signaling for Akt and Mapk, and the ability to transform cells in culture (PMID: 26703895).",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 55729,
        "geneSymbol": "ATF7IP",
        "terms": [
            "ATF7IP",
            "AM",
            "ATF-IP",
            "MCAF",
            "MCAF1",
            "p621"
        ]
    },
    "variant": "ATF7IP - PDGFRB",
    "createDate": "08/24/2016",
    "updateDate": "08/24/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5159,
                "geneSymbol": "PDGFRB",
                "terms": [
                    "PDGFRB",
                    "CD140B",
                    "IBGC4",
                    "IMF1",
                    "JTK12",
                    "KOGS",
                    "PDGFR",
                    "PDGFR-1",
                    "PDGFR1",
                    "PENTT"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 7933,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 treatment induced cell death of transformed cells expressing ATF7IP-PDGFRB in culture (PMID: 26703895).",
            "molecularProfile": {
                "id": 26105,
                "profileName": "ATF7IP - PDGFRB"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7929,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ATF7IP-PDGFRB demonstrated sensitivity to treatment with Bafetinib (NS-187) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26105,
                "profileName": "ATF7IP - PDGFRB"
            },
            "therapy": {
                "id": 661,
                "therapyName": "Bafetinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7920,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ATF7IP-PDGFRB demonstrated sensitivity to treatment with Sprycel (dasatinib) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26105,
                "profileName": "ATF7IP - PDGFRB"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7919,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ATF7IP-PDGFRB demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26105,
                "profileName": "ATF7IP - PDGFRB"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7931,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD98059 treatment induced cell death of transformed cells expressing ATF7IP-PDGFRB in culture (PMID: 26703895).",
            "molecularProfile": {
                "id": 26105,
                "profileName": "ATF7IP - PDGFRB"
            },
            "therapy": {
                "id": 2617,
                "therapyName": "PD98059",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7927,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ATF7IP-PDGFRB demonstrated sensitivity to treatment with Tasigna (nilotinib) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26105,
                "profileName": "ATF7IP - PDGFRB"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7930,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ATF7IP-PDGFRB demonstrated sensitivity to treatment with Rebastinib (DCC-2036) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26105,
                "profileName": "ATF7IP - PDGFRB"
            },
            "therapy": {
                "id": 1045,
                "therapyName": "Rebastinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7928,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ATF7IP-PDGFRB demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in decreased cell viability (PMID: 26703895).",
            "molecularProfile": {
                "id": 26105,
                "profileName": "ATF7IP - PDGFRB"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7932,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, U0126 treatment induced cell death of transformed cells expressing ATF7IP-PDGFRB in culture (PMID: 26703895).",
            "molecularProfile": {
                "id": 26105,
                "profileName": "ATF7IP - PDGFRB"
            },
            "therapy": {
                "id": 2427,
                "therapyName": "U0126",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6526,
                    "pubMedId": 26703895,
                    "title": "Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703895"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26105,
            "profileName": "ATF7IP - PDGFRB",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}